Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients

• Status: Completed
• Trial end date: 2011-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The parameter that best correlates with 5 years disease-free survival (DFS ) in patients (pts) with localized rectal cancer (RC) is the pathological TNM staging (ypTNM) after chemo-radiotherapy (Ch-RT). DFS is 97% in pts with ypT0N0M0 = ypCR and 42% in pts with ypN +. Standard 5-FU Ch-RT achieves 15% of ypCR. The use of IMRT achieves a high proportion of ypCR . This study aimed to demonstrate in a prospective manner the feasibility of personalizing Ch regimen base in TT in combination with IMRT in patients with RC. Secondary objectives included the number of ypCR and safety.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Grupo Hospital de Madrid
• Treatments: Oxaliplatin

Criteria

Inclusion Criteria:

• Histologic diagnosis of rectal adenocarcinoma.

• Clinical stage II or III.

• Feasible patient for neoadjuvant Ch-RT.

• Availability of tumor tissue or possibility of a tumor biopsy to define therapeutic targets.

• Informed written consent was obtained from all patients

Exclusion Criteria:

• Contraindication to the administration of any of the drugs used in the study capecitabine, irinotecan, oxaliplatin, cetuximab or bevacizumab.